Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome—A Randomized Controlled Trial

Sympathetic nervous system (SNS) activity is increased in polycystic ovary syndrome (PCOS). Moxonidine is a centrally acting sympatholytic drug with known beneficial effects on hypertension, insulin sensitivity, dyslipidemia and inflammation. In this double-blind placebo controlled randomized clinic...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Soulmaz Shorakae, Elisabeth A. Lambert, Eveline Jona, Carolina Ika Sari, Barbora de Courten, John B. Dixon, Gavin W. Lambert, Helena J. Teede
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2018-10-01
Rangatū:	Frontiers in Physiology
Ngā marau:	polycystic ovary syndrome sympathetic nervous system insulin resistance moxonidine randomized controlled trial
Urunga tuihono:	https://www.frontiersin.org/article/10.3389/fphys.2018.01486/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!